Medicare Patients Face Higher Drug Costs Despite $2,000 Spending Cap

Health plans that provide prescription drug benefits to Medicare beneficiaries have responded to the Inflation Reduction Act's $2,000 cap on out-of-pocket costs for prescription drugs by raising patient cost-sharing through higher deductibles and a greater reliance on coinsurance, finds a new study recently published in JAMA Internal Medicine.